文献速递临床试验与 GCP

ProPAC-COVID 试验:阿奇霉素与羟氯喹预防性治疗的统计分析计划

Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan.
PubMed 文献 · Trials · 2020-10-20

ProPAC-COVID 是一项多中心、随机、安慰剂对照、双盲临床试验,评估阿奇霉素联合羟氯喹能否缩短 COVID-19 住院患者的住院时间,并降低无创通气、ICU 治疗和死亡风险。本文详细描述了该试验主要和次要终点的统计分析计划,旨在防止选择性报告并提高透明度。

要点

  • 主要终点为随机化后 14 天内存活且未住院的天数。
  • 分析采用意向性治疗原则,并进行改良 ITT 和符合方案分析。
  • 随机化按年龄、招募中心和慢性肺病分层,采用未知区组大小。

核心结论

  • 本文发布 ProPAC-COVID 试验的统计分析计划,以确保结果报告透明并防止选择性报告。

研究设计与样本

  • 多中心、随机、安慰剂对照、双盲临床试验,评估阿奇霉素联合羟氯喹治疗住院 COVID-19 患者。
  • 随机化采用未知区组大小,并按年龄、招募中心和慢性肺病分层。
  • 主要分析采用意向性治疗原则,并进行改良 ITT 和符合方案分析。

关键数值与推荐

  • 主要终点为随机化后 14 天内存活且未住院的天数。
  • 次要终点包括无创通气、ICU 治疗和死亡风险。

局限性

  • 患者入组仍在进行中,本文仅为统计分析计划,尚未报告试验结果。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: There is an urgent need for treatments that can shorten hospitalization and lower the risk of secondary infection and death in patients with corona disease. The ProPac-COVID trial evaluates whether combination therapy with macrolide azithromycin and hydroxychloroquine via anti-inflammation/immune modulation, antiviral efficacy, and pre-emptive treatment of supra-infections can shorten hospitalization duration and reduce the risk of non-invasive ventilation, treatment in the intensive care unit, and death in patients with acute hospital admission and a positive test for 2019-nCoV and symptoms of COVID-19 disease. METHODS: The ProPAC-COVID is a multi-center, randomized, placebo-controlled, double-blinded clinical trial. The primary outcome is number of days spent alive and out of hospital within 14 days from randomization. Randomization will be in blocks of unknown size, and the final allocation will be stratified for age, site of recruitment, and whether the patient has any chronic lung diseases. Data is analyzed using intention-to-treat (ITT) principles, and main analyses will also be subject to modified ITT analysis and per protocol analysis. DISCUSSION: This paper describes the detailed statistical analysis plan for the evaluation of primary and secondary endpoints of the ProPAC-COVID study. Enrolment of patients to the ProPAC-COVID study is still ongoing. The purpose of this paper is to provide primary publication of study results to prevent selective reporting of outcomes, data-driven analysis, and to increase transparency. TRIAL REGISTRATION: ClinicalTrials.gov NCT04322396 . Registered on 26 March 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sivapalan P, Ulrik CS, Lappere TS, et al. Proactive prophylaxis with azithromycin and hydroxychloroquine in hospitalized patients with COVID-19 (ProPAC-COVID): a statistical analysis plan. Trials. 2020. PMID: 33081817. doi:10.1186/s13063-020-04795-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。